leisure time
Previous article:
FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article: Sarepta Duchenne therapy fails to meet primary endpoint in trial
Next article: Sarepta Duchenne therapy fails to meet primary endpoint in trial
explore
hotspot
-
Lilly's Alzheimer's drug donanemab backed by FDA advisers
2025-10-04 04:01 -
5 takeaways from STAT's examination of Zynex Medical
2025-10-04 03:52 -
DeepMind touts AlphaFold's new skills as protein folding AI models face off
2025-10-04 03:50 -
Live blog: Hearing on CRISPR
2025-10-04 03:25 -
Coercive sterilizations revealed by STAT prompt outrage
2025-10-04 02:06 -
Brain injuries and the importance of a second opinion
2025-10-04 02:02